86 results about "Large-cell lymphoma" patented technology

The invention is applicable to the technical field of clinical medicine, provides a clinical multi-modal cancer drug response prediction method based on feature reconstruction, constructs a clinical multi-modal model for drug response prediction of diffuse large B-cell lymphoma, and aims to predict the drug response of diffuse large B-cell lymphoma by integrating gene sequencing and clinical multi-modal data. And accurate drug reaction prediction is realized. The model adopts an end-to-end multi-stage processing flow: firstly, extracting gene features through TransP-Net, and processing multi-modal clinical data by using a clinical information encoder; then, pseudo-gene features are generated through a clinical-genome filling module to deal with the data missing problem; and finally, multi-modal deep fusion is realized through a clinical information decoder, and a prediction result is output. According to the method, data characteristics and working processes in a real clinical environment are fully considered, two conditions of complete gene data and missing gene data can be processed at the same time, and the method has a good clinical transformation prospect and application value.

Purinostat mesylate (PM) for preventing and treating diffuse large B-cell lymphoma (DLBCL), an analogue thereof, a drug for combined use, and the use. PM exhibits excellent in-vivo and in-vitro anti-tumor therapeutic effects on DLBCL (DEL and DHL) subtypes with poor prognosis, DLBCL subtypes having TP53 deletion and mutation combined with a plurality of poor prognosis gene mutations, and DLBCL having TP53 mutation with double expressors, which are superior to that of most existing DLBCL clinical therapy plans. A doublet or triplet therapy of PM with rituximab, R-CHOP, venetoclax and R-CHP also exhibits excellent in-vivo therapeutic effects against DLBCL and a plurality of subtypes. Thus, PM and the drug for combined use have an important clinical significance for the DLBCL and a plurality of subtypes.

The invention relates to the technical field of biological medicine detection, and discloses tsRNA for predicting, diagnosing or monitoring diffuse large B-cell lymphoma, a kit and application of the tsRNA. The marker comprises one or more of six tsRNAs including tsRNA-Leu-CAG, tsRNA-Pro-CG, tsRNA-Gln-CTG, tsRNA-Cys-GCA, tsRNA-Leu-AAG, tsRNA-Lys-CTT and the like, and the nucleotide sequence of the marker is as shown in SEQ ID NO. 1-6; the nucleotide sequence of the marker is as shown in SEQ ID NO. By detecting the change of the expression level of tsRNA in peripheral blood serum, early diagnosis, dynamic monitoring of treatment response and prognosis evaluation of DLBCL can be realized.

The invention discloses a prognosis evaluation method and system for diffuse large B-cell lymphoma. According to the method, firstly, a gene module closely related to lipid metabolism is screened from DLBCL transcriptome data through weighted gene co-expression network analysis (WGCNA), and then eight key prognosis genes including FNDC1, IL22RA2, C15orf48, OMD, MFAP2, BC017398, CXCL6 and TNFAIP6 are identified from the module by adopting multi-step regression analysis (single factor Cox, LASSO and multi-factor Cox). A risk scoring model is constructed based on the expression levels and regression coefficients of the genes, and DLBCL patients can be divided into a high-risk group and a low-risk group with significant survival differences. The risk score and the clinical pathological factors are further integrated to construct a column graph, and individualized survival probability prediction can be achieved. The invention further provides a corresponding prognosis evaluation system, electronic equipment and a storage medium. An independent data set verifies that the prognosis model has excellent prediction performance and clinical practical value.

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and / or have relapsed or not responded to a prior chemotherapy.

The invention discloses an application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma, relates to the technical field of disease prognosis and molecular biology, provides a marker for prognosis evaluation of diffuse large B-cell lymphoma, and relates to the application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma. The invention relates to application of a substance for detecting the marker in claim 1 in preparation of a product for prognosis evaluation of diffuse large B-cell lymphoma, and provides a medicine for treating diffuse large B-cell lymphoma. By detecting the marker, the malignancy degree of the DLBCL can be more accurately analyzed, a reliable prognosis evaluation basis is provided for clinicians, and accurate prognosis evaluation is carried out; through targeting NF-kappa B and MUM1 dual-blocking therapeutic drugs, the prognosis of patients is improved, the life quality and the survival rate of the patients are improved, and novel therapeutic drugs are developed; a new breakthrough is brought to diagnosis, treatment and prognosis evaluation of the DLBCL, and potential clinical application value is achieved.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

The invention provides application of zinc pyrithione and copper pyrithione in treatment of lymphoma, and discovers that zinc pyrithione and copper pyrithione have an obvious inhibition effect on proliferation of diffuse large B-cell lymphoma cells, and the inhibition effect is relatively good. Therefore, the zinc pyrithione can be used for preparing the medicine for treating the lymphoma, especially diffuse large B-cell lymphoma, and is used for clinically treating the lymphoma. The invention provides a new scheme and strategy for treatment of lymphoma, especially diffuse large B-cell lymphoma, provides a new choice for drug-resistant patients, and is relatively low in treatment cost.

The application discloses an index combination for identifying diffuse large B-cell lymphoma and application thereof. The index combination is composed of gender, age and eight oligosaccharide chains, namely NGA2F, NG2FB, NG1A2F-1, NG1A2F-2, NA2F, NA2FB, NA3Fb and NA4Fb. The application also provides a prediction model, a prediction system, a computer readable storage medium and a kit constructed based on the index combination. Experimental results show that the prediction model has a sensitivity of 88.06%, a specificity of 92.98% and an AUC of 0.949 in identifying diffuse large B-cell lymphoma in a verification set. The application realizes, for the first time, non-invasive, rapid and high-accuracy identification of diffuse large B-cell lymphoma based on blood oligosaccharide chains combined with clinical indexes, and provides a brand-new tool for auxiliary differential diagnosis of patients with lymph node enlargement.

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.

This invention relates to the field of molecular diagnostics, specifically providing a diagnostic kit for the combined detection of DLBCL based on plasma exosomal miRNAs. This invention provides two or more peripheral blood exosomes used as diagnostic biomarkers for diffuse large B-cell lymphoma (DLBCL). Based on these DLBCL diagnostic biomarkers, this invention also provides a non-invasive, highly reproducible, and highly specific plasma exosomal miRNA diagnostic kit for the early diagnosis and follow-up monitoring of DLBCL. The plasma exosomal miRNA diagnostic kit provided by this invention is of great significance in the early diagnosis, genotyping, relapse monitoring, and efficacy evaluation of DLBCL.

The application discloses Lactobacillus reuteri and application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicine. The application provides application of Lactobacillus reuteri and / or a metabolite thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, wherein the Lactobacillus reuteri is Lactobacillus reuteri (HG001). Limosilactobacillus reuteri The Lactobacillus reuteri is separated from feces of healthy people and used for preparation of the medicine for treating diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of diffuse large B-cell lymphoma and can improve side effects caused by cyclophosphamide treatment of diffuse large B-cell lymphoma; and the Lactobacillus reuteri and the cyclophosphamide have a synergistic effect in treatment of diffuse large B-cell lymphoma.

The embodiment of the present application discloses a genotype classification method for diffuse large B-cell lymphoma, a computer device, and a computer-readable storage medium. The method includes the following steps: testing a sample according to a preset specific gene set to obtain variation detection data; preprocessing the variation detection data to obtain variation information; generating an initial feature matrix based on the variation information, screening the initial feature matrix to obtain a feature matrix, and the feature matrix is ​​used to characterize the gene variation contained in the specific gene set in the corresponding sample; obtaining a first genotype label and an important feature set, constructing a data set based on the feature matrix, the first genotype label, and the important feature set, and training a classification model; obtaining a second genotype label output by the classification model, and determining a genotype classification report based on the second genotype label. Therefore, the present application can reduce the cost of testing, can effectively predict the patient's genotype, and has a high clinical application value.

The present invention relates to a method for in vitro or ex vivo diagnosis of the chances of survival of a patient suffering from diffuse large-scale B-cell lymphoma (DLBCL) comprising a step of detecting the expression of at least one of the newly identified LBCL biomarker genes.

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20 / anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and / or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and / or etoposide.

The present invention relates to a method for in vitro or ex vivo diagnosis of the chances of survival of a patient suffering from diffuse large-scale B-cell lymphoma (DLBCL) comprising a step of detecting the expression of at least one of the newly identified LBCL biomarker genes.

The application discloses a new use of androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, namely, application of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in preparation of a medicine for treating lymphoma. 50 The IC value of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in the SR cell line is detected by a CCK-8 method, and the cytotoxicity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione on human umbilical vein endothelial cells Huvce and human immortalized keratinocytes Hacat is detected, in the body, the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione significantly inhibits tumor growth and shows good biological safety and no systemic toxicity; TUNEL staining, gamma-H2AX staining and neutral comet experiment prove that the compound of the application inhibits the growth of SR by causing serious damage to DNA, the application not only adds the diversity of the biological activity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, but also provides a new direction for developing a new medicine for treating lymphoma.

The invention relates to the technical field of disease prognosis and molecular biology, in particular to application of immune-related polygenes in prognosis evaluation of diffuse large B-cell lymphoma. The biomarkers are DES, CHIT1, FGF14, CCR4, CTLA4 and VGF (Vertical Growth Factor). According to the method, core genes related to immunity are screened on the basis of diffuse large B cell lymphoma transcriptome data such as GEO and TCGA, and a multi-gene immune model: RS = (-0.0306) * DES + (-0.4683) * CHIT1 + (1.1418) * FGF14 + (0.1132) * CCR4 + (-0.07) * CTLA4 + (-0.3463) * VGF is constructed; according to the immune polygene immune model, diffuse large B-cell lymphoma patients can be divided into high and low RS groups, the survival prognosis of high-RS people is proved to be obviously lower than that of low-RS people, and the survival prognosis can be used as an independent prognosis index.

The invention provides application of a biomarker in serum detected by a Raman spectrum in preparation of a product for predicting or detecting non-Hodgkin lymphoma, and belongs to the technical field of medical diagnosis. A spectroscopy basis is provided for mass serological detection data of a patient and early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma, and important information is provided for rapid early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma.

A lymphoma recurrence risk prediction method, device and equipment based on MRD are disclosed, comprising: acquiring clinical feature information related to diffuse large B-cell lymphoma; in response to the clinical feature information, calculating a plurality of baseline clinical features through a structured constraint target Bayesian network model to obtain an initial recurrence risk probability of diffuse large B-cell lymphoma of a target object; the structure constraint is used to prohibit direct connection between each baseline clinical feature; according to the initial recurrence risk probability, the state of minimal residual disease related to diffuse large B-cell lymphoma and high-risk pathological factors, the multidimensional calculation of recurrence risk is carried out through the target random forest model to obtain the final recurrence risk probability of the target object; according to the final recurrence risk probability, the recurrence risk information of diffuse large B-cell lymphoma of the target object is generated. To improve the interpretability and accuracy of lymphoma recurrence risk prediction.

The invention discloses application of a reagent for detecting intestinal flora in preparation of a diffuse large B-cell lymphoma diagnosis or staging kit, and the reagent for detecting the intestinal flora is used for detecting the species abundance of the intestinal flora. The intestinal flora comprises short-chain fatty acid producing bacteria, enterococcus strains, helicobacter strains, saccharomycetes strains and pathogenic fungi. It is found that intestinal flora of a DLBCL patient shows significant dynamic evolution from a healthy period to an advanced disease period, and the core feature of the intestinal flora is subversive reconstruction of an interaction network of short-chain fatty acid producing bacteria and fungi. Therefore, by detecting the species abundance of the intestinal flora and analyzing the interaction strength of each community in the intestinal flora, the disease course of the DLBCL of the patient can be quickly and effectively evaluated by stages; in addition, 13 key strain variables screened from the intestinal flora have excellent DLBCL diagnosis performance, and a rapid and effective new way is provided for DLBCL diagnosis or staging.

The invention discloses application of an SETD8 inhibitor in preparation of a medicine for treating diffuse large B-cell lymphoma, and belongs to the technical field of biological medicine. The SETD8 inhibitor is preferably UNC0379, and the diffuse large B-cell lymphoma comprises a hair growth center B-cell-like lymphoma and a non-hair growth center B-cell-like lymphoma. The medicine prepared from the SETD8 inhibitor can effectively inhibit proliferation of diffuse large B-cell lymphoma cells, induce apoptosis of the diffuse large B-cell lymphoma cells and inhibit growth of in-vivo diffuse large B-cell lymphoma tumor cells. The invention also provides a pharmaceutical composition for treating diffuse large B-cell lymphoma, which comprises the SETD8 inhibitor as an active component and is supplemented with a pharmaceutically acceptable carrier or auxiliary material. The application range of the SETD8 inhibitor is expanded, a new drug choice is provided for solving the problem that in an existing treatment scheme, drug resistance or relapse of a diffuse large B-cell lymphoma patient is prone to occurring, and the SETD8 inhibitor has important clinical application value.

This invention discloses the application of methylene blue in the preparation of drugs for treating lymphoma, belonging to the field of therapeutic drug technology. This invention creatively discovers that methylene blue can be used as a drug for treating lymphoma, exhibiting cytotoxic effects against human diffuse large B-cell lymphoma cell lines including U2932, TMD8, SUDHL-4, and OCI-LY19, as well as human peripheral T-cell lymphoma cell lines including KARPAS299, SMZ-1, and KHYG-1, and its in vitro activity is superior to first-line chemotherapy drugs. This invention provides an effective option for researching lymphoma treatment strategies and preparing new drugs for treating lymphoma.

The application belongs to the technical field of biological medicine, and it is found for the first time that the expression level of SF3B1 in the lymph node tissue of a diffuse large B-cell lymphoma (DLBCL) patient is significantly higher than that in the lymph node tissue of a reactive lymphadenitis patient, and the high expression of SF3B1 is related to poor prognosis of DLBCL; moreover, it is also found that the expression of SF3B1 in DLBCL cells is inhibited by a SF3B1 inhibitor, which can inhibit the proliferation of DLBCL cells and promote the apoptosis of DLBCL cells, and in a DLBCL orthotopic tumor model, the SF3B1 inhibitor can effectively inhibit tumor growth, exhibit anti-tumor activity and controllable safety. Therefore, the SF3B1 gene or SF3B1 protein can be used as a target to screen drugs for relieving and / or treating DLBCL, and the SF3B1 inhibitor can be used for relieving or / and treating tumors.

The invention discloses a diffuse large B-cell lymphoma prognostic diagnosis marker combination and application thereof. The marker combination disclosed by the invention comprises TCF4 and AURKA. Bioinformatics exploration is utilized, immunohistochemical staining is further utilized to confirm that expression up-regulation of AURKA and TCF4 in clinical DLBCL cases is related to poor prognosis of patients, and the two molecules have a co-expression relationship with c-MYC. Researches prove that AURKA and TCF4 are markers for poor prognosis of DLBCL patients, TCF4 is a potential target spot in DLBCL treatment, a new prognostic marker is provided for DLBCL, and a theoretical basis is provided for further exploration of a treatment strategy of combined use of the AURKA and an AURKA inhibitor.

The invention belongs to the technical field of medicines, and particularly relates to application of a pharmaceutical composition in treatment of diffuse large B-cell lymphoma. Specifically, two groups of pharmaceutical compositions, namely the magnolin and the vonacrah as well as the masitinib and the gemcitabine hydrochloride, are found, and the molar ratio of the magnolin to the vonacrah is (40-120): (0.2-0.8). The molar ratio of masitinib to gemcitabine hydrochloride is (1-10): (1-10). Research finds that the pharmaceutical composition can synergistically inhibit growth of DLBCL cells, provides a novel combined treatment scheme for clinical treatment of DLBCL, and has a wide clinical application prospect.